Trial Profile
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKS.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2011
Price :
$35
*
At a glance
- Drugs Ivermectin (Primary) ; Metronidazole
- Indications Bacterial infections; Rosacea
- Focus Therapeutic Use
- Sponsors Galderma
- 14 Jun 2011 New trial record